You are here

FDA Approves Liquid Form of Cytarabine

SCHAUMBURG, Ill., Jan. 20 /PRNewswire-FirstCall/ -- American Pharmaceutical Partners, Inc. , today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the Abbreviated New Drug Application (ANDA) of cytarabine injection, 2 g, 100 mg/mL liquid, 20 mL single-dose vials. The U.S. market for all dosages of cytarabine for injection in liquid and lyophilized forms was approximately $6 million in 2002.

"We believe cytarabine injection in the liquid form is the most desirable as it requires less handling prior to administration," said Patrick Soon-Shiong, M.D., APP chairman, president and chief executive officer. "Cytarabine injection is APP's first ANDA approval of 2004 and brings to 14 the number of anti-cancer products in the company's product offering. APP is committed to developing and providing a broad array of quality injectable products in the oncology, anti-infective and critical care areas."

The generic equivalent of Sicor, Inc.'s Cytosar-U®, cytarabine injection, in combination with other approved anti-cancer drugs, is indicated for remission induction in acute non-lymphocytic leukemia of adults and pediatric patients. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia.

Source: American Pharmaceutical Partners, Inc.

More Headlines

PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
National Statistics Report Factors In Race, Ethnicity for the First Time
FDA Prioritizing Review of ARB Applications to Help Mitigate Drug Shortage
California Woman Claimed Asbestos in Talc-Based Powder Caused Her Mesothelioma
Synergistic Effects Seen When Combined With Cisplatin in Mice
For Locally Advanced or Metastatic Triple-Negative Type Only